Danaher Corporation (FRA:DAP)
Germany · Delayed Price · Currency is EUR | Market Cap | 121.05B |
| Revenue (ttm) | 20.50B |
| Net Income (ttm) | 2.91B |
| Shares Out | n/a |
| EPS (ttm) | 4.02 |
| PE Ratio | 41.56 |
| Forward PE | 24.11 |
| Dividend | 1.07 (0.64%) |
| Ex-Dividend Date | Jun 27, 2025 |
| Volume | 289 |
| Average Volume | 668 |
| Open | 169.58 |
| Previous Close | 168.18 |
| Day's Range | 166.12 - 169.58 |
| 52-Week Range | 149.72 - 258.00 |
| Beta | n/a |
| RSI | 36.79 |
| Earnings Date | Oct 21, 2025 |
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manuf... [Read more]
Financial Performance
In 2024, Danaher's revenue was $23.88 billion, a decrease of -0.06% compared to the previous year's $23.89 billion. Earnings were $3.90 billion, a decrease of -17.79%.
Financial numbers in USD Financial StatementsNews
DANAHER INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Danaher Corporation - DHR
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Danaher Corporatio...
mRNA Biotechs - Long-Term Value Risks Abound
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...
How Do Investors Really Feel About Danaher?
Danaher's (NYSE: DHR) short percent of float has risen 12.03% since its last report. The company recently reported that it has 9.47 million shares sold short , which is 1.49% of all regular shares th...
$1000 Invested In Danaher 10 Years Ago Would Be Worth This Much Today
Danaher (NYSE: DHR) has outperformed the market over the past 10 years by 1.07% on an annualized basis producing an average annual return of 13.56%. Currently, Danaher has a market capitalization of ...
iA Global Buys the Dip in Danaher's Stock Price
EQUITY ALERT: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential breaches of fiduciary duties by the directors and officers of Danaher Corporation (NYSE: DHR). If you current...
EQUITY ALERT: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential breaches of fiduciary duties by the directors and officers of Danaher Corporation ...
Analysts' Top S&P 500 Stocks to Buy Now
Broadcom, Microsoft and Amazon.com are just three names making the Street's list of top-rated stocks this month. Some of the other equities might surprise you.
Danaher Stock Closes Near Day's High After Key Trading Signal
DHR reverses early down move after Alert Danaher Corp. (NYSE: DHR) experienced a Power Inflow today, a significant event for those who follow where smart money goes and value order flow analytics in ...
Danaher Stock Closes Near Day's High After Key Trading Signal
DHR reverses early down move after Alert
Danaher Appoints Jonathan Leiken as General Counsel
WASHINGTON , July 31, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Jonathan Leiken has been appointed Senior Vic...
Investors decided the good outweighs the bad with Danaher, says Jim Cramer
'Mad Money' host Jim Cramer talks how to play Danaher after earnings.
Investors decided the good outweighs the bad with Danaher, says Jim Cramer
'Mad Money' host Jim Cramer talks how to play Danaher after earnings.
Danaher Q2 2025 Update
Danaher Stock: Attractively Valued And Poised For Growth Acceleration
Danaher Corporation thrives on bioprocessing demand & diagnostics resilience. Click for why, with solid execution & 80% recurring revenue, DHR offers upside.
Danaher Raises 2025 Earnings Outlook
Danaher Lifts 2025 Earnings Outlook Amid Biotech Growth, Cost Discipline
Danaher Corp (NYSE: DHR) on Tuesday reported second-quarter 2025 sales of $5.94 billion, up 3.5% year-over-year, beating the consensus of $5.84 billion . The life science giant reported adjusted earn...
Danaher raises full-year EPS guidance to $7.70-$7.80 amid robust bioprocessing growth and portfolio resilience
Danaher Corporation (DHR) Q2 2025 Earnings Call Transcript
Danaher (DHR) Q2 2025 Earnings Call Transcript
Cramer's Stop Trading: Danaher
Jim Cramer breaks down why he's keeping an eye on shares of Danaher.
Cramer's Stop Trading: Danaher
Jim Cramer breaks down why he's keeping an eye on shares of Danaher.
Danaher slips despite Q2 beat as Life Sciences unit underperforms
Danaher lifts annual profit view on strength in diagnostics, names new CFO
Life sciences firm Danaher raised its annual profit forecast on Tuesday, banking on resilient demand for its diagnostic testing tools and services.